Literature DB >> 26876939

mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress.

Young Sung Yun1, Kwan Hyun Kim1, Barbara Tschida2, Zohar Sachs3, Klara E Noble-Orcutt4, Branden S Moriarity5, Teng Ai6, Rui Ding6, Jessica Williams6, Liqiang Chen6, David Largaespada7, Do-Hyung Kim8.   

Abstract

Reduction of translational fidelity often occurs in cells with high rates of protein synthesis, generating defective ribosomal products. If not removed, such aberrant proteins can be a major source of cellular stress causing human diseases. Here, we demonstrate that mTORC1 promotes the formation of immunoproteasomes for efficient turnover of defective proteins and cell survival. mTORC1 sequesters precursors of immunoproteasome β subunits via PRAS40. When activated, mTORC1 phosphorylates PRAS40 to enhance protein synthesis and simultaneously to facilitate the assembly of the β subunits for forming immunoproteasomes. Consequently, the PRAS40 phosphorylations play crucial roles in clearing aberrant proteins that accumulate due to mTORC1 activation. Mutations of RAS, PTEN, and TSC1, which cause mTORC1 hyperactivation, enhance immunoproteasome formation in cells and tissues. Those mutations increase cellular dependence on immunoproteasomes for stress response and survival. These results define a mechanism by which mTORC1 couples elevated protein synthesis with immunoproteasome biogenesis to protect cells against protein stress.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26876939      PMCID: PMC4870089          DOI: 10.1016/j.molcel.2016.01.013

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  36 in total

1.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

2.  The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome.

Authors:  M Groettrup; S Standera; R Stohwasser; P M Kloetzel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response.

Authors:  Sylvia Heink; Daniela Ludwig; Peter-M Kloetzel; Elke Krüger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-08       Impact factor: 11.205

4.  Immunoproteasomes: regulating the regulator.

Authors:  Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

5.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Authors:  Emilie Vander Haar; Seong-Il Lee; Sricharan Bandhakavi; Timothy J Griffin; Do-Hyung Kim
Journal:  Nat Cell Biol       Date:  2007-02-04       Impact factor: 28.824

6.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control.

Authors:  Robbie Loewith; Estela Jacinto; Stephan Wullschleger; Anja Lorberg; José L Crespo; Débora Bonenfant; Wolfgang Oppliger; Paul Jenoe; Michael N Hall
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

7.  Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly.

Authors:  P Chen; M Hochstrasser
Journal:  Cell       Date:  1996-09-20       Impact factor: 41.582

8.  PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.

Authors:  Lifu Wang; Thurl E Harris; Richard A Roth; John C Lawrence
Journal:  J Biol Chem       Date:  2007-05-17       Impact factor: 5.157

9.  The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.

Authors:  Noriko Oshiro; Rinako Takahashi; Ken-ichi Yoshino; Keiko Tanimura; Akio Nakashima; Satoshi Eguchi; Takafumi Miyamoto; Kenta Hara; Kenji Takehana; Joseph Avruch; Ushio Kikkawa; Kazuyoshi Yonezawa
Journal:  J Biol Chem       Date:  2007-05-21       Impact factor: 5.157

10.  PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.

Authors:  Bruno D Fonseca; Ewan M Smith; Vivian H-Y Lee; Carol MacKintosh; Christopher G Proud
Journal:  J Biol Chem       Date:  2007-06-29       Impact factor: 5.157

View more
  32 in total

1.  Decreased levels of constitutive proteasomes in experimental autoimmune encephalomyelitis may be caused by a combination of subunit displacement and reduced Nfe2l1 expression.

Authors:  Kara L Shanley; Che-Lin Hu; Oscar A Bizzozero
Journal:  J Neurochem       Date:  2019-12-02       Impact factor: 5.372

2.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

3.  PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling.

Authors:  Wei Yang; Li-Feng Yang; Zhi-Qi Song; Syed Zahid Ali Shah; Yong-Yong Cui; Chao-Si Li; Hua-Fen Zhao; Hong-Li Gao; Xiang-Mei Zhou; De-Ming Zhao
Journal:  CNS Neurosci Ther       Date:  2017-03-14       Impact factor: 5.243

4.  Sulfur Partitioning between Glutathione and Protein Synthesis Determines Plant Growth.

Authors:  Anna Speiser; Marleen Silbermann; Yihan Dong; Stefan Haberland; Veli Vural Uslu; Shanshan Wang; Sajid A K Bangash; Michael Reichelt; Andreas J Meyer; Markus Wirtz; Ruediger Hell
Journal:  Plant Physiol       Date:  2018-05-11       Impact factor: 8.340

5.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

Review 6.  The Immunoproteasome in oxidative stress, aging, and disease.

Authors:  Helen K Johnston-Carey; Laura C D Pomatto; Kelvin J A Davies
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-04-20       Impact factor: 8.250

Review 7.  Molecular logic of mTORC1 signalling as a metabolic rheostat.

Authors:  Alexander J Valvezan; Brendan D Manning
Journal:  Nat Metab       Date:  2019-03-04

Review 8.  Positioning of proteasome inhibitors in therapy of solid malignancies.

Authors:  Margot S F Roeten; Jacqueline Cloos; Gerrit Jansen
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-28       Impact factor: 3.333

Review 9.  The role of the proteasome in AML.

Authors:  C M Csizmar; D-H Kim; Z Sachs
Journal:  Blood Cancer J       Date:  2016-12-02       Impact factor: 11.037

Review 10.  PRAS40 signaling in tumor.

Authors:  Dan Lv; Lianying Guo; Ting Zhang; Lin Huang
Journal:  Oncotarget       Date:  2017-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.